A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-04

Target enrollment:

Participant gender:

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

PHASE1

UCB Biopharma SRL